Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.
about
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyDNA repair targeted therapy: The past or future of cancer treatment?DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerTargeting the Checkpoint to Kill Cancer CellsPhase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced CancerA phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.Targeting lung cancer through inhibition of checkpoint kinases.Lack of Casein Kinase 1 Delta Promotes Genomic Instability - The Accumulation of DNA Damage and Down-Regulation of Checkpoint Kinase 1ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.The cell cycle checkpoint inhibitors in the treatment of leukemias.Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma.Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.ATR/CHK1 inhibitors and cancer therapy.Directing the use of DDR kinase inhibitors in cancer treatment.LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
P2860
Q26745686-E941AD5D-D5AE-487B-A00A-46FB60EC6757Q26768679-0A8C4BDD-F686-40A0-ADA8-94F880EB190EQ26776513-CC929700-96E4-4CCF-8578-899FE3B4A5E4Q26795781-B9AB8E70-089C-403B-A7D4-DC0080F2BA08Q33431248-15D786ED-E977-4506-843F-1FCE3BCA4F80Q33439342-98779A1E-D74D-4828-AF22-AC148B868A21Q33798999-F5C1975A-19CB-4635-9944-7C34505F6BB5Q35128547-7210FFA0-8A5D-4FD2-BB07-42E216B555A3Q36261341-64192D71-804E-44B8-98EB-46F9F45DAD87Q36739002-A57AFBEC-AE27-429B-AA99-4B31530B410AQ36771796-8580C464-B6DE-4623-B589-039C4528F770Q37376388-0D44AF04-C422-4A7E-8B30-5630053A1103Q37634102-C9CFBF1D-A1B6-466E-9EA3-594A3C0C5362Q38868502-6F74BCEA-6E26-47A9-8280-51B849C205E1Q38901610-EE55C75A-F72D-40F0-B896-641197987222Q39650689-2596E41B-1EE7-4768-87BE-202C38F9D19FQ47130816-00D573D8-60D3-47CD-8E9D-351DAA72859BQ47622968-B1F4463E-5B09-4114-AD51-094C9E5D0BBDQ47687840-7EDFB0FB-375E-41CB-9F00-B4B13381B3D1Q55035826-79054C2D-682B-40BF-BE65-DCCCE05FFBF5
P2860
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Preclinical analyses and phase ...... patients with advanced cancer.
@en
type
label
Preclinical analyses and phase ...... patients with advanced cancer.
@en
prefLabel
Preclinical analyses and phase ...... patients with advanced cancer.
@en
P2093
P2860
P1476
Preclinical analyses and phase ...... patients with advanced cancer.
@en
P2093
Aimee Bence Lin
Beatrice Voss
Darlene Barnard
Elizabeth Kumm
Farhana F Merzoug
H Bruce Diaz
Lysiane Huber
Mark Marshall
Martin Sebastian
P2860
P2888
P304
P356
10.1007/S10637-014-0114-5
P577
2014-06-20T00:00:00Z
P5875
P6179
1040224664